Article
Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.
Gastroenterology - 1 Apr 2014
Fung Scott, Kwan Peter, Fabri Milotka, Horban Andrzej, Pelemis Mijomir, Hann Hie-Won, Gurel Selim, Caruntu Florin A, Flaherty John F, Massetto Benedetta, Dinh Phillip, Corsa Amoreena, Subramanian G Mani, McHutchison John G, Husa Petr, Gane Edward
Abstract excerpt
BACKGROUND & AIMS: Tenofovir disoproxil fumarate (TDF) is active against lamivudine-resistant hepatitis B virus (HBV) infection, but data to support its clinical efficacy in this setting are limited. METHODS: In a prospective, double-blind, 96-week trial, patients were randomly assigned (1:1) to groups given TDF (300 mg, n = 141) or a combination of emtricitabine (FTC, 200 mg; n = 139) and TDF (300 mg, FTC/TDF)....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.